Kevin Joseph Fitzgerald's most recent trade in Ovid Therapeutics Inc was a trade of 17,578 Common Stock done at an average price of $2.6 . Disclosure was reported to the exchange on April 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc | Kevin Joseph Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 2.56 per share. | 07 Apr 2026 | 17,578 | 17,578 (0%) | 0% | 2.6 | 45,000 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 323.25 per share. | 04 Mar 2026 | 233 | 20,870 (0%) | 0% | 323.2 | 75,317 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 323.84 per share. | 04 Mar 2026 | 210 | 21,359 (0%) | 0% | 323.8 | 68,006 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 326.24 per share. | 04 Mar 2026 | 153 | 20,569 (0%) | 0% | 326.2 | 49,915 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 324.60 per share. | 04 Mar 2026 | 148 | 20,722 (0%) | 0% | 324.6 | 48,041 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 321.81 per share. | 04 Mar 2026 | 124 | 21,103 (0%) | 0% | 321.8 | 39,904 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 323.01 per share. | 04 Mar 2026 | 96 | 21,569 (0%) | 0% | 323.0 | 31,009 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 321.82 per share. | 04 Mar 2026 | 79 | 21,665 (0%) | 0% | 321.8 | 25,424 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 324.88 per share. | 04 Mar 2026 | 75 | 21,284 (0%) | 0% | 324.9 | 24,366 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 320.81 per share. | 04 Mar 2026 | 59 | 21,744 (0%) | 0% | 320.8 | 18,928 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 325.67 per share. | 04 Mar 2026 | 57 | 21,227 (0%) | 0% | 325.7 | 18,563 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 319.03 per share. | 04 Mar 2026 | 29 | 21,831 (0%) | 0% | 319.0 | 9,252 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 320.00 per share. | 04 Mar 2026 | 28 | 21,803 (0%) | 0% | 320 | 8,960 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 8,105 | 8,105 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 3,688 | 25,110 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 320.51 per share. | 02 Mar 2026 | 722 | 22,219 (0%) | 0% | 320.5 | 231,408 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 326.81 per share. | 02 Mar 2026 | 392 | 24,323 (0%) | 0% | 326.8 | 128,110 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 321.58 per share. | 02 Mar 2026 | 359 | 21,860 (0%) | 0% | 321.6 | 115,447 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 327.67 per share. | 02 Mar 2026 | 329 | 23,994 (0%) | 0% | 327.7 | 107,803 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 316.55 per share. | 02 Mar 2026 | 289 | 23,223 (0%) | 0% | 316.6 | 91,483 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 318.62 per share. | 02 Mar 2026 | 282 | 22,941 (0%) | 0% | 318.6 | 89,851 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 325.63 per share. | 02 Mar 2026 | 258 | 24,715 (0%) | 0% | 325.6 | 84,013 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 329.71 per share. | 02 Mar 2026 | 170 | 23,724 (0%) | 0% | 329.7 | 56,051 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 328.71 per share. | 02 Mar 2026 | 100 | 23,894 (0%) | 0% | 328.7 | 32,871 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 331.93 per share. | 02 Mar 2026 | 94 | 23,549 (0%) | 0% | 331.9 | 31,201 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 324.66 per share. | 02 Mar 2026 | 90 | 24,973 (0%) | 0% | 324.7 | 29,219 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 330.85 per share. | 02 Mar 2026 | 81 | 23,643 (0%) | 0% | 330.9 | 26,799 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 323.62 per share. | 02 Mar 2026 | 47 | 25,063 (0%) | 0% | 323.6 | 15,210 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 332.65 per share. | 02 Mar 2026 | 37 | 23,512 (0%) | 0% | 332.6 | 12,308 | Common Stock |
| Ovid Therapeutics Inc | Kevin Joseph Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 65,000 | 65,000 | - | - | Employee Stock Option (Right to Buy) | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2026 | 158 | 21,422 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 4,000 | 25,264 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 331.96 per share. | 12 Feb 2026 | 2,041 | 21,264 (0%) | 0% | 332.0 | 677,532 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 310.08 per share. | 12 Feb 2026 | 1,959 | 23,305 (0%) | 0% | 310.1 | 607,448 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2026 | 3,800 | 25,064 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 370.00 per share. | 11 Jan 2026 | 644 | 22,151 (0%) | 0% | 370 | 238,280 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 368.76 per share. | 11 Jan 2026 | 562 | 22,795 (0%) | 0% | 368.8 | 207,243 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 371.24 per share. | 11 Jan 2026 | 485 | 21,666 (0%) | 0% | 371.2 | 180,051 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 372.93 per share. | 11 Jan 2026 | 280 | 21,386 (0%) | 0% | 372.9 | 104,420 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 365.56 per share. | 11 Jan 2026 | 220 | 23,846 (0%) | 0% | 365.6 | 80,423 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 364.83 per share. | 11 Jan 2026 | 199 | 24,066 (0%) | 0% | 364.8 | 72,601 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 367.52 per share. | 11 Jan 2026 | 197 | 23,357 (0%) | 0% | 367.5 | 72,401 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 360.22 per share. | 11 Jan 2026 | 155 | 24,483 (0%) | 0% | 360.2 | 55,834 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 358.18 per share. | 11 Jan 2026 | 123 | 24,723 (0%) | 0% | 358.2 | 44,056 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 374.33 per share. | 11 Jan 2026 | 122 | 21,264 (0%) | 0% | 374.3 | 45,668 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 361.45 per share. | 11 Jan 2026 | 98 | 24,385 (0%) | 0% | 361.4 | 35,422 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 357.17 per share. | 11 Jan 2026 | 96 | 24,846 (0%) | 0% | 357.2 | 34,288 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 368.62 per share. | 11 Jan 2026 | 92 | 23,663 (0%) | 0% | 368.6 | 33,913 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 359.14 per share. | 11 Jan 2026 | 85 | 24,638 (0%) | 0% | 359.1 | 30,527 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 362.38 per share. | 11 Jan 2026 | 73 | 24,312 (0%) | 0% | 362.4 | 26,454 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 366.42 per share. | 11 Jan 2026 | 50 | 23,796 (0%) | 0% | 366.4 | 18,321 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 363.55 per share. | 11 Jan 2026 | 47 | 24,265 (0%) | 0% | 363.6 | 17,087 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 355.17 per share. | 11 Jan 2026 | 42 | 24,983 (0%) | 0% | 355.2 | 14,917 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 356.10 per share. | 11 Jan 2026 | 41 | 24,942 (0%) | 0% | 356.1 | 14,600 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 367.39 per share. | 11 Jan 2026 | 41 | 23,755 (0%) | 0% | 367.4 | 15,063 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 369.48 per share. | 11 Jan 2026 | 40 | 23,623 (0%) | 0% | 369.5 | 14,779 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 353.95 per share. | 11 Jan 2026 | 39 | 25,025 (0%) | 0% | 353.9 | 13,804 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 375.63 per share. | 11 Jan 2026 | 19 | 23,569 (0%) | 0% | 375.6 | 7,137 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 370.89 per share. | 11 Jan 2026 | 19 | 23,604 (0%) | 0% | 370.9 | 7,047 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 377.80 per share. | 11 Jan 2026 | 15 | 23,554 (0%) | 0% | 377.8 | 5,667 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 374.43 per share. | 11 Jan 2026 | 14 | 23,588 (0%) | 0% | 374.4 | 5,242 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 372.50 per share. | 11 Jan 2026 | 2 | 23,602 (0%) | 0% | 372.5 | 745 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 449.00 per share. | 17 Nov 2025 | 8,168 | 25,224 (0%) | 0% | 449 | 3,667,432 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 8,161 | 839 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.13 per share. | 17 Nov 2025 | 8,161 | 33,392 (0%) | 0% | 119.1 | 972,220 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 458.41 per share. | 17 Nov 2025 | 794 | 23,211 (0%) | 0% | 458.4 | 363,978 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 460.84 per share. | 17 Nov 2025 | 707 | 21,882 (0%) | 0% | 460.8 | 325,814 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 459.89 per share. | 17 Nov 2025 | 622 | 22,589 (0%) | 0% | 459.9 | 286,052 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 455.24 per share. | 17 Nov 2025 | 368 | 24,631 (0%) | 0% | 455.2 | 167,528 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 456.25 per share. | 17 Nov 2025 | 364 | 24,267 (0%) | 0% | 456.3 | 166,075 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 461.96 per share. | 17 Nov 2025 | 323 | 21,559 (0%) | 0% | 462.0 | 149,213 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 463.08 per share. | 17 Nov 2025 | 295 | 21,264 (0%) | 0% | 463.1 | 136,609 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 457.39 per share. | 17 Nov 2025 | 262 | 24,005 (0%) | 0% | 457.4 | 119,836 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 451.51 per share. | 17 Nov 2025 | 129 | 24,999 (0%) | 0% | 451.5 | 58,245 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 450.09 per share. | 17 Nov 2025 | 96 | 25,128 (0%) | 0% | 450.1 | 43,209 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 2,851 | 27,672 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 2,102 | 24,821 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 452.69 per share. | 01 Oct 2025 | 555 | 25,892 (0%) | 0% | 452.7 | 251,243 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 450.81 per share. | 01 Oct 2025 | 449 | 26,723 (0%) | 0% | 450.8 | 202,414 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 451.86 per share. | 01 Oct 2025 | 276 | 26,447 (0%) | 0% | 451.9 | 124,713 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 453.77 per share. | 01 Oct 2025 | 273 | 25,619 (0%) | 0% | 453.8 | 123,879 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 449.79 per share. | 01 Oct 2025 | 207 | 27,172 (0%) | 0% | 449.8 | 93,107 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 454.84 per share. | 01 Oct 2025 | 203 | 25,416 (0%) | 0% | 454.8 | 92,333 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 448.77 per share. | 01 Oct 2025 | 150 | 27,379 (0%) | 0% | 448.8 | 67,316 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 457.43 per share. | 01 Oct 2025 | 122 | 25,234 (0%) | 0% | 457.4 | 55,806 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 446.53 per share. | 01 Oct 2025 | 96 | 27,576 (0%) | 0% | 446.5 | 42,867 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 455.82 per share. | 01 Oct 2025 | 60 | 25,356 (0%) | 0% | 455.8 | 27,349 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 447.91 per share. | 01 Oct 2025 | 47 | 27,529 (0%) | 0% | 447.9 | 21,052 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 457.67 per share. | 01 Oct 2025 | 3 | 25,231 (0%) | 0% | 457.7 | 1,373 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 2,851 | 24,115 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 454.04 per share. | 15 Aug 2025 | 543 | 22,972 (0%) | 0% | 454.0 | 246,544 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 452.96 per share. | 15 Aug 2025 | 329 | 23,515 (0%) | 0% | 453.0 | 149,024 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 454.84 per share. | 15 Aug 2025 | 241 | 22,731 (0%) | 0% | 454.8 | 109,616 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 451.99 per share. | 15 Aug 2025 | 103 | 23,844 (0%) | 0% | 452.0 | 46,555 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 449.92 per share. | 15 Aug 2025 | 90 | 23,986 (0%) | 0% | 449.9 | 40,493 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 450.92 per share. | 15 Aug 2025 | 39 | 23,947 (0%) | 0% | 450.9 | 17,586 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 447.97 per share. | 15 Aug 2025 | 39 | 24,076 (0%) | 0% | 448.0 | 17,471 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 455.83 per share. | 15 Aug 2025 | 12 | 22,719 (0%) | 0% | 455.8 | 5,470 | Common Stock |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 7,763 | 21,264 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,819 | 7,819 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 3,871 | 16,256 (0%) | 0% | 0 | Common Stock |